新辅助化疗对肺癌组织中MMP-2与TIMP-2表达的影响  

Comparasion of expressions of MMP-2 and TIMP-2 after NACT of lung carcinoma

作　　者：王伦青[1] 沈毅[2] 张哲[1] 尹志伊[1] 何宝亮[1] 唐国建[1] 

机构地区：[1]青岛市市立医院,山东青岛266073 [2]青岛大学医学院附属医院

出　　处：《山东医药》2008年第36期13-14,共2页Shandong Medical Journal

基　　金：青岛市科技发展计划项目(C3-1-NY-14-3)。

摘　　要：目的观察非小细胞肺癌(NSCLC)对新辅助化疗(NACT)敏感度及对癌组织中基质金属蛋白酶(MMP)-2和基质金属蛋白酶抑制剂(TIMP)-2表达的影响。方法应用免疫组化法检测NACT后NSCLC(NACT组)和未经化疗的NSCLC(对照组)组织中MMP-2和TIMP-2的表达。结果NACT组鳞癌与低分化癌中MMP-2水平较对照组下降(P<0.05),而在腺癌和中高分化癌中,两组均无变化(P>0.05)。结论NSCLC中鳞癌比腺癌对NACT更敏感,低分化癌比中高分化癌对NACT更敏感。Objective To observe the sensitiveness of nonsmall-cell lung cancer（NSCLC） for neoadjuvant chemotherapy（NACT） through the expression of matrix metalloproteinase-2 （MMP-2） and matrix metallo-proteinase inhibitor-2 （TIMP-2） in carcinoma tissue post NACT. Methods Detected the expressions of MMP-2, TIMP-2 in different NSCLC group （ NACT group and no NACT control group） by immunohistochemical method. Results The expression of MMP-2 was no table lower in squamous carcinoma and poorly differentiated of NACT group than that of control group（ P 〈 0.05 ）, but there was no significant different between the adenocarcinoma and moderately-well-differentiated carcinoma. Conclusion For NSCLC, NACT is more sensitive in squamous and poorly differentiated carcinoma than adenocarcinoma and mod- erately-well-differentiated carcinoma.

关 键 词：肺肿瘤 基质金属蛋白酶-2 基质金属蛋白酶抑制剂-2 新辅助化疗疗法 

分 类 号：R733[医药卫生—肿瘤]